MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Alnylam Pharmaceuticals Inc

Suletud

SektorTervishoid

255.3 -5.29

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

254.95

Max

269.45

Põhinäitajad

By Trading Economics

Sissetulek

28M

-84M

Müük

92M

593M

Aktsiakasum

0.06

Kasumimarginaal

-14.121

Töötajad

2,230

EBITDA

-92M

-155M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+19.74% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-46M

35B

Eelmine avamishind

260.59

Eelmine sulgemishind

255.3

Uudiste sentiment

By Acuity

84%

16%

361 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Alnylam Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. sept 2024, 17:01 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12. sept 2024, 11:00 UTC

Peamised uudised

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Võrdlus sarnastega

Hinnamuutus

Alnylam Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

19.74% tõus

12 kuu keskmine prognoos

Keskmine 323.33 USD  19.74%

Kõrge 500 USD

Madal 206 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Alnylam Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

22 ratings

18

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

253.11 / 271.02Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

361 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.